Orphazyme Logo

Orphazyme

ISIN: DK0060910917 | Ticker: ORPHA | LEI: 54930025OZD2GGSQ7L42
Sector: Health CareSub-Industry: Biotechnology
Country: Denmark

About Orphazyme

Company Description

Orphazyme was founded in Denmark in 2009 on a scientific discovery about the role of heat shock proteins (HSPs), which was described in a well-cited article published in the journal Nature.

We translated this scientific discovery into late-stage clinical trials of our investigational drug candidate, arimoclomol, with the aim of developing new treatment options for people with neurodegenerative diseases, such as Niemann-Pick disease type-C (NPC).

In May 2022, substantially all of Orphazyme’s assets and business activities, including those relating to the development and approval of arimoclomol, were sold to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc.

Year founded

2009

Headquarters

Ole Maaløes Vej 3, 2200 Copenhagen – Denmark

Financial statements

Download as Excel
Line item in (dkk) 01.01.2019 01.01.2020 01.01.2021 01.07.2021 01.01.2022 01.07.2022 01.01.2023 01.07.2023
Assets N/A N/A 822,493,000.00 N/A 173,229,000.00 93,589,000.00 58,122,000.00 36,181,000.00
Noncurrent Assets N/A N/A 38,829,000.00 N/A 14,285,000.00 5,500,000.00 0.00 N/A
Property Plant And Equipment N/A N/A 4,687,000.00 N/A 2,985,000.00 0.00 0.00 N/A
Intangible Assets Other Than Goodwill N/A N/A 12,454,000.00 N/A 2,152,000.00 0.00 0.00 N/A
Deferred Tax Assets N/A N/A 2,065,000.00 N/A 0.00 0.00 N/A N/A
Current Tax Assets Noncurrent N/A N/A 2,750,000.00 N/A 2,750,000.00 5,500,000.00 0.00 N/A
Current Assets N/A N/A 783,664,000.00 N/A 158,944,000.00 88,089,000.00 58,122,000.00 36,181,000.00
Inventories N/A N/A 0.00 N/A 0.00 N/A 0.00 N/A
Current Trade Receivables N/A N/A 0.00 N/A 29,268,000.00 23,765,000.00 4,103,000.00 0.00
Current Tax Assets Current N/A N/A 5,500,000.00 N/A 7,229,000.00 7,388,000.00 7,338,000.00 5,500,000.00
Cash and cash equivalents N/A N/A 726,929,000.00 334,184,000.00 102,255,000.00 49,532,000.00 42,464,000.00 30,340,000.00
Cash 394,706,000.00 123,588,000.00 726,929,000.00 N/A 102,255,000.00 49,532,000.00 42,464,000.00 30,340,000.00
Equity And Liabilities N/A N/A 822,493,000.00 N/A 173,229,000.00 93,589,000.00 58,122,000.00 36,181,000.00
Equity 388,249,000.00 52,969,000.00 620,525,000.00 166,761,000.00 9,339,000.00 78,205,000.00 41,667,000.00 28,883,000.00
Issued Capital N/A N/A 34,698,000.00 N/A 34,952,000.00 35,312,000.00 35,312,000.00 35,312,000.00
Retained Earnings N/A N/A -1,502,921,000.00 N/A -2,110,998,000.00 -2,046,990,000.00 -2,080,588,000.00 -2,093,372,000.00
Share Premium N/A N/A 2,082,254,000.00 N/A 2,082,486,000.00 2,087,436,000.00 2,087,436,000.00 2,087,436,000.00
Other Reserves N/A N/A 6,494,000.00 N/A 2,899,000.00 2,447,000.00 -493,000.00 -493,000.00
Noncurrent Liabilities N/A N/A 35,341,000.00 N/A 34,798,000.00 0.00 98,000.00 N/A
Other Noncurrent Liabilities N/A N/A 1,634,000.00 N/A 98,000.00 0.00 98,000.00 N/A
Longterm Borrowings N/A N/A 23,830,000.00 N/A 2,482,000.00 0.00 0.00 N/A
Current Liabilities N/A N/A 166,627,000.00 N/A 129,092,000.00 15,384,000.00 16,357,000.00 7,298,000.00
Current Provisions N/A N/A 0.00 N/A 0.00 N/A N/A N/A
Current Tax Liabilities Current N/A N/A 4,159,000.00 N/A 584,000.00 334,000.00 284,000.00 0.00
Other Current Liabilities N/A N/A 53,327,000.00 N/A 29,523,000.00 3,688,000.00 1,075,000.00 5,510,000.00
Line item in (dkk) 01.01.2019/
01.01.2020
01.01.2020/
01.01.2021
01.01.2021/
01.07.2021
01.01.2021/
01.01.2022
01.01.2022/
01.07.2022
01.01.2022/
01.01.2023
01.01.2023/
01.07.2023
Revenue 0.00 0.00 0.00 0.00 0.00 0.00 N/A
Profit Loss From Operating Activities -335,954,000.00 -608,534,000.00 -57,344,000.00 -633,303,000.00 -27,296,000.00 N/A -12,834,000.00
Finance Income 316,000.00 2,444,000.00 25,000.00 37,000.00 56,000.00 193,000.00 50,000.00
Finance Costs 7,359,000.00 29,071,000.00 0.00 0.00 0.00 0.00 N/A
Profit Loss Before Tax -342,997,000.00 -635,161,000.00 -57,319,000.00 -83,436,000.00 -27,239,000.00 -41,048,000.00 -12,784,000.00
Income Tax Expense Continuing Operations -5,500,000.00 -1,915,000.00 -2,318,000.00 -4,941,000.00 -2,793,000.00 -2,736,000.00 0.00
Profit Loss From Continuing Operations N/A N/A -55,002,000.00 -78,495,000.00 -24,446,000.00 -38,312,000.00 -12,784,000.00
Profit Loss From Discontinued Operations N/A N/A -408,778,000.00 -548,044,000.00 87,429,000.00 64,382,000.00 0.00
Profit (loss) -337,497,000.00 -633,246,000.00 -463,780,000.00 -626,539,000.00 62,983,000.00 26,070,000.00 -12,784,000.00
Line item in (dkk) 01.01.2020 01.01.2021 01.07.2021 01.01.2022 01.07.2022 01.01.2023 01.07.2023
Profit (loss) -337,497,000.00 -633,246,000.00 -463,780,000.00 -626,539,000.00 62,983,000.00 26,070,000.00 -12,784,000.00
Adjustments For Income Tax Expense -5,500,000.00 -1,915,000.00 N/A -4,941,000.00 N/A N/A N/A
Adjustments For Finance Costs 7,359,000.00 29,071,000.00 N/A 10,608,000.00 N/A N/A N/A
Adjustments For Depreciation And Amortisation Expense 3,803,000.00 5,200,000.00 N/A 18,111,000.00 N/A 1,820,000.00 N/A
Adjustments For Unrealised Foreign Exchange Losses Gains 0.00 0.00 N/A 0.00 N/A N/A N/A
Adjustments For Sharebased Payments 2,549,000.00 28,105,000.00 N/A 16,019,000.00 N/A 1,773,000.00 N/A
Interest Paid Classified As Operating Activities 5,181,000.00 10,723,000.00 N/A 6,263,000.00 N/A 1,132,000.00 N/A
Interest Received Classified As Operating Activities 388,000.00 45,000.00 N/A 37,000.00 N/A 193,000.00 N/A
Income Taxes Paid Refund Classified As Operating Activities N/A N/A 4,181,000.00 N/A 0.00 N/A N/A
Cash Flows From Used In Operating Activities -326,818,000.00 -539,076,000.00 2,591,000.00 -602,571,000.00 -116,472,000.00 -117,945,000.00 -12,124,000.00
Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities N/A N/A N/A 0.00 N/A 88,887,000.00 N/A
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities 0.00 0.00 N/A 1,040,000.00 N/A 1,460,000.00 N/A
Purchase Of Property Plant And Equipment Classified As Investing Activities 2,777,000.00 2,365,000.00 0.00 92,000.00 0.00 0.00 N/A
Purchase Of Intangible Assets Classified As Investing Activities 508,000.00 2,736,000.00 0.00 902,000.00 0.00 0.00 N/A
Cash Flows From Used In Investing Activities -3,285,000.00 -5,101,000.00 0.00 46,000.00 0.00 90,347,000.00 N/A
Proceeds From Issuing Shares 19,000.00 1,280,786,000.00 464,000.00 464,000.00 5,310,000.00 5,451,000.00 0.00
Proceeds From Borrowings Classified As Financing Activities 62,758,000.00 0.00 N/A 0.00 N/A N/A N/A
Repayments Of Borrowings Classified As Financing Activities 0.00 10,535,000.00 N/A 25,657,000.00 N/A 39,155,000.00 N/A
Payments Of Lease Liabilities Classified As Financing Activities 3,838,000.00 2,970,000.00 N/A 3,503,000.00 N/A 1,233,000.00 N/A
Cash Flows From Used In Financing Activities 58,939,000.00 1,159,422,000.00 -1,148,000.00 -30,344,000.00 5,310,000.00 -35,078,000.00 0.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes -271,164,000.00 615,245,000.00 N/A -632,869,000.00 N/A N/A N/A
Effect Of Exchange Rate Changes On Cash And Cash Equivalents 46,000.00 -11,904,000.00 5,311,000.00 8,195,000.00 -5,138,000.00 2,885,000.00 0.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A N/A -398,056,000.00 -632,869,000.00 -47,585,000.00 -62,676,000.00 -12,124,000.00
Cash and cash equivalents N/A 726,929,000.00 334,184,000.00 102,255,000.00 49,532,000.00 42,464,000.00 30,340,000.00

Please note that some sums might not add up.

Filings & Publications

2023

Report
Q1
H1
Q3
FY
Consolidated Report
ENG
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2022

Report
Q1
H1
Q3
FY
Consolidated Report
ENG
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2021

Report
Q1
H1
Q3
FY
Consolidated Report
ENG
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

DK0060910917

LEI

54930025OZD2GGSQ7L42

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Nasdaq Copenhagen

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.